Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$7.80	$6.71	$5.01 ▼ $18.71	$46.50M	0.3	125,136 shs	79,059 shs
DTIL Precision BioSciences	$4.92 -1.0%	$4.95	$3.61 ▼ $13.32	$55.11M	1.55	184,247 shs	36,104 shs
KPTI Karyopharm Therapeutics	$4.53 +1.1%	$5.06	$3.51 ▼ $17.40	$39.14M	0.33	81,879 shs	89,685 shs
TSBX Turnstone Biologics	$0.32 -6.4%	$0.35	$0.29 ▼ $3.05	$7.48M	1.29	213,985 shs	107,037 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	+9.70%	+3.86%	+12.88%	-44.29%
DTIL Precision BioSciences	-1.01%	+6.03%	-5.93%	-8.72%	-59.90%
KPTI Karyopharm Therapeutics	+1.12%	-2.37%	-28.66%	-43.02%	-68.62%
TSBX Turnstone Biologics	-6.59%	-4.77%	-4.09%	-16.20%	-87.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.2624 of 5 stars	3.3	3.0	4.7	2.8	2.5	0.6
DTIL Precision BioSciences	3.7644 of 5 stars	3.5	2.0	4.6	1.0	1.7	0.6
KPTI Karyopharm Therapeutics	4.0105 of 5 stars	3.5	0.0	4.6	3.6	2.5	0.6
TSBX Turnstone Biologics	3.194 of 5 stars	2.8	5.0	0.0	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	127.56% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	855.28% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	853.64% Upside
TSBX Turnstone Biologics	1.50	Reduce	$0.45	39.23% Upside

Current Analyst Ratings Breakdown

Latest TSBX, KPTI, DTIL, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
3/28/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/19/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/11/2025	ATRA Atara Biotherapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$199.73M	0.23	N/A	N/A	($24.34) per share	-0.32
DTIL Precision BioSciences	$51.14M	1.07	N/A	N/A	$4.53 per share	1.09
KPTI Karyopharm Therapeutics	$142.13M	0.28	N/A	N/A	($1.47) per share	-3.08
TSBX Turnstone Biologics	$19.31M	0.39	N/A	N/A	$4.27 per share	0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$276.13M	-$3.72	N/A	N/A	N/A	-132.58%	N/A	-90.16%	8/11/2025 (Estimated)
DTIL Precision BioSciences	-$61.32M	-$2.01	82.01	N/A	N/A	11.48%	-23.69%	-6.98%	7/30/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)
TSBX Turnstone Biologics	-$55.20M	-$2.73	N/A	N/A	N/A	N/A	-105.99%	-87.27%	8/13/2025 (Estimated)

Latest TSBX, KPTI, DTIL, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/8/2025	Q1 2025	TSBX Turnstone Biologics	-$0.26	-$0.51	-$0.25	-$0.51	N/A	N/A
3/28/2025	Q4 2024	TSBX Turnstone Biologics	-$0.69	-$0.56	+$0.13	-$0.56	N/A	N/A
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million
3/7/2025	Q4 2024	ATRA Atara Biotherapeutics	-$3.82	-$1.19	+$2.63	-$1.19	$20.58 million	$32.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
TSBX Turnstone Biologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.59	0.50
DTIL Precision BioSciences	0.34	9.22	9.22
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
TSBX Turnstone Biologics	N/A	3.75	3.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
DTIL Precision BioSciences	37.99%
KPTI Karyopharm Therapeutics	66.44%
TSBX Turnstone Biologics	52.51%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	3.70%
DTIL Precision BioSciences	4.50%
KPTI Karyopharm Therapeutics	2.75%
TSBX Turnstone Biologics	32.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.55 million	Optionable
DTIL Precision BioSciences	200	11.09 million	7.36 million	No Data
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable
TSBX Turnstone Biologics	82	23.14 million	15.70 million	Not Optionable

TSBX, KPTI, DTIL, and ATRA Headlines

Recent News About These Companies

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...

May 8, 2025 | gurufocus.com

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

May 8, 2025 | globenewswire.com

Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year

March 31, 2025 | markets.businessinsider.com

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

March 28, 2025 | investing.com

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

March 28, 2025 | globenewswire.com

Turnstone Biologics stock plunges to 52-week low of $0.4

February 11, 2025 | msn.com

Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?

February 7, 2025 | zacks.com

Turnstone Biologics to explore strategic alternatives

February 6, 2025 | thepharmaletter.com

Turnstone ends last remaining clinical program due to costs, plots more layoffs

February 5, 2025 | fiercebiotech.com

Turnstone Biologics halts TIDAL-01 development, seeks alternatives

February 5, 2025 | msn.com

Turnstone Biologics downgraded to Neutral from Overweight at Piper Sandler

February 5, 2025 | markets.businessinsider.com

Turnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True Potential

February 5, 2025 | bovnews.com

Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review

February 4, 2025 | quiverquant.com

Turnstone Biologics Announces Plans to Explore Strategic Alternatives

February 4, 2025 | finance.yahoo.com

BofA downgrades Turnstone to Underperform on unfavorable market

November 16, 2024 | markets.businessinsider.com

Turnstone Biologics downgraded to Underperform from Neutral at BofA

November 16, 2024 | markets.businessinsider.com

Leerink Partners Keeps Their Hold Rating on Turnstone Biologics Corp. (TSBX)

November 15, 2024 | markets.businessinsider.com

Turnstone Biologics Faces Financial and Operational Challenges

November 14, 2024 | markets.businessinsider.com

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

November 12, 2024 | markets.businessinsider.com

What’s Behind the 18.75% Gain in Turnstone Biologics Corp (TSBX) Stock? Find Out Now!

November 7, 2024 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSBX, KPTI, DTIL, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$7.80 0.00 (0.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$7.82 +0.02 (+0.26%)

As of 05/29/2025 07:06 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Precision BioSciences NASDAQ:DTIL

$4.92 -0.05 (-1.01%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$4.85 -0.07 (-1.50%)

As of 05/29/2025 06:17 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Karyopharm Therapeutics NASDAQ:KPTI

$4.53 +0.05 (+1.12%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$4.53 0.00 (-0.11%)

As of 05/29/2025 06:50 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Turnstone Biologics NASDAQ:TSBX

$0.32 -0.02 (-6.43%)

Closing price 05/29/2025 03:58 PM Eastern

Extended Trading

$0.33 +0.01 (+2.41%)

As of 05/29/2025 04:42 PM Eastern

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time